Document is current
Any future updates will be listed below
-
Authors
Schattgen, Stefan A. https://orcid.org/0000-0002-6860-5079
Turner, Jackson S. https://orcid.org/0000-0002-4396-6265
Ghonim, Mohamed A.
Crawford, Jeremy Chase https://orcid.org/0000-0003-4096-6048
Schmitz, Aaron J.
Kim, Hyunjin
Zhou, Julian Q. https://orcid.org/0000-0001-9602-2092
Awad, Walid
Mettelman, Robert C. https://orcid.org/0000-0002-3527-5616
Kim, Wooseob
McIntire, Katherine M.
Haile, Alem
Klebert, Michael K.
Suessen, Teresa
Middleton, William D.
Teefey, Sharlene A.
Presti, Rachel M.
Ellebedy, Ali H. https://orcid.org/0000-0002-6129-2532
Thomas, Paul G. https://orcid.org/0000-0001-7955-0256
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U01AI144616, R01AI136514, F32AI157296)
- License Information
-
More Information
Article History
Received: 28 August 2023
Accepted: 11 July 2024
First Online: 20 August 2024
Competing interests
: A.H.E. is a consultant for InBios and Fimbrion Therapeutics. The Ellebedy Laboratory received funding under sponsored research agreements from Emergent BioSolutions. P.G.T. has consulted and/or received honoraria and travel support from Pfizer, Merck, Illumina, Johnson and Johnson and 10x Genomics, and serves on the Scientific Advisory Board of Immunoscape, Shennon Bio and Cytoagents. The authors have applied for patents covering some aspects of these studies. All other authors declare no competing interests.
